I remember Marc Garneau
I had been at Johnson for a couple of days, as a reporter covering the shuttle flight of Canadian astronaut Steve MacLean, and I remember being struck by the sheer size of the place – some 100 buildings on more than 1,600 acres of land.
And, of course, that giant, brash flag.
I first met Marc Garneau, Canada's first astronaut, on Oct. 24, 1992, at JSC, where he was with the Canadian Space Agency. MacLean's shuttle had been launched from Kennedy Space Center two days earlier and I had flown across the U.S. to follow the flight from mission control at JSC.
Marc Garneau, first Canadian in space, remembered for aspirations he held for his country
That Saturday evening, there was also some baseball being played.
The Toronto Blue Jays, leading the World Series with the Atlanta Braves 3-2, were in the Georgia city for Game 6. After filing my report for the day to the Toronto Star, I joined other journalists and members of the Canadian Space Agency in a hotel room to watch the game.
Garneau, as I recall, was not expected, owing to pressure of work on the mission, but showed up anyway, a couple of innings into the game. Someone had organized a betting pool, in which you picked a number. If that number turned out to equal the sum of the runs scored in the game, you took the kitty.
As it happened, both Garneau and I had 7; the Jays won the game 4-3 to take their first World Series so Garneau and I shared the small prize.
The party broke up soon after the game ended. The shuttle mission was still under way and we all had work the next day.
That Sunday, as I drove into the JSC complex, I noticed an oddity.
Atop the flagpole, above the U.S. flag, was a small red and white banner. Somehow, the Maple Leaf had been hoisted during the night. And because it was Sunday, with only the shuttle mission staff on the premises, it stayed there all day.
When it comes to space, Canada has always reached for the stars
I met Garneau a couple of times later, in the course of my work as The Star's science reporter, and asked him about the flag.
He said he couldn't possibly comment.
You can find more obituaries from The Globe and Mail here.
To submit a memory about someone we have recently profiled on the Obituaries page, e-mail us at obit@globeandmail.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
11 hours ago
- CTV News
Honeybee swarming season begins in Nova Scotia
As honeybee swarming season begins in Nova Scotia, a local beekeeper gives tips on what to do if you see this phenomenon in the wild. Swarming usually occurs in the spring and is a honeybee colony's way of reproducing and expanding their colony. While a swarm can often contain tens of thousands of bees, Graham McGuire, a hobby beekeeper in Halifax, says they're mostly docile if left alone. 'Honeybee swarms are usually anywhere from a maybe a cantaloupe size to over a basketball size, and it's a solid mass of bees hanging all together and there would obviously be some in flight around it. So they do look a little different from a wasp or a hornet, and that sort of swarming, clumping behavior is very distinctive to honeybees.' Honeybees can be identified through several features like their size - being smaller than wasps, hornets, and bumblebees - as well as having slightly more muted colours. Honeybees also lack any hair on their bodies. Anyone who comes across a swarm is recommended by McGuire to contact the Nova Scotia Beekeepers Association as they maintain a list of swarms and can dispatch beekeepers to move them to a safe space if needed. 'If you don't know what you're doing with them obviously it's best to call a professional, and the Nova Scotia Beekeeper's association tries to work with hobby beekeepers all around the province to make sure the bees instead of being exterminated end up in a safe place.' With files from CTV's Jim Kvammen. For more Nova Scotia news, visit our dedicated provincial page.
CTV News
13 hours ago
- CTV News
Major reports about how climate change affects the US are removed from websites
WASHINGTON — Legally mandated U.S. national climate assessments seem to have disappeared from the federal websites built to display them, making it harder for state and local governments and the public to learn what to expect in their backyards from a warming world. Scientists said the peer-reviewed authoritative reports save money and lives. Websites for the national assessments and the U.S. Global Change Research Program were down Monday and Tuesday with no links, notes or referrals elsewhere. The White House, which was responsible for the assessments, said the information will be housed within NASA to comply with the law, but gave no further details. Searches for the assessments on NASA websites did not turn them up. NASA did not respond to requests for information. The U.S. National Oceanic and Atmospheric Administration, which coordinated the information in the assessments, did not respond to repeated inquiries. 'It's critical for decision makers across the country to know what the science in the National Climate Assessment is. That is the most reliable and well-reviewed source of information about climate that exists for the United States,' said University of Arizona climate scientist Kathy Jacobs, who coordinated the 2014 version of the report. 'It's a sad day for the United States if it is true that the National Climate Assessment is no longer available,' Jacobs said. 'This is evidence of serious tampering with the facts and with people's access to information, and it actually may increase the risk of people being harmed by climate-related impacts.' Harvard climate scientist John Holdren, who was President Obama's science advisor and whose office directed the assessments, said after the 2014 edition he visited governors, mayors and other local officials who told him how useful the 841-page report was. It helped them decide whether to raise roads, build seawalls and even move hospital generators from basements to roofs, he said. 'This is a government resource paid for by the taxpayer to provide the information that really is the primary source of information for any city, state or federal agency who's trying to prepare for the impacts of a changing climate,' said Texas Tech climate scientist Katharine Hayhoe, who has been a volunteer author for several editions of the report. Copies of past reports are still squirreled away in NOAA's library. NASA's open science data repository includes dead links to the assessment site. The most recent report, issued in 2023, included an interactive atlas that zoomed down to the county level. It found that climate change is affecting people's security, health and livelihoods in every corner of the country in different ways, with minority and Native American communities often disproportionately at risk. The 1990 Global Change Research Act requires a national climate assessment every four years and directs the president to establish an interagency United States Global Change Research Program. In the spring, the Trump administration told the volunteer authors of the next climate assessment that their services weren't needed and ended the contract with the private firm that helps coordinate the website and report. Additionally, NOAA's main website was recently forwarded to a different NOAA website. Social media and blogs at NOAA and NASA about climate impacts for the general public were cut or eliminated. 'It's part of a horrifying big picture,' Holdren said. 'It's just an appalling whole demolition of science infrastructure.' The national assessments are more useful than international climate reports put out by the United Nations every seven or so years because they are more localized and more detailed, Hayhoe and Jacobs said. The national reports are not only peer reviewed by other scientists, but examined for accuracy by the National Academy of Sciences, federal agencies, the staff and the public. Hiding the reports would be censoring science, Jacobs said. And it's dangerous for the country, Hayhoe said, comparing it to steering a car on a curving road by only looking through the rearview mirror: 'And now, more than ever, we need to be looking ahead to do everything it takes to make it around that curve safely. It's like our windshield's being painted over.' Associated Press writer Will Weissert contributed to this report. The Associated Press' climate and environmental coverage receives financial support from multiple private foundations. AP is solely responsible for all content. Find AP's standards for working with philanthropies, a list of supporters and funded coverage areas at Seth Borenstein, The Associated Press
Globe and Mail
14 hours ago
- Globe and Mail
ImmunoGenesis Announces the Formation of Scientific Advisory Board
Initial meeting of Scientific Advisory Board (SAB) convened to discuss the first-in-human phase 1a/ 1b clinical trial of IMGS-001, a dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON , July 1, 2025 /CNW/ -- ImmunoGenesis, a clinical-stage biotech company developing innovative, science-driven immunotherapies is encouraged by the early performance of IMGS-001 in the ongoing Phase 1a dose escalation study in adult patients with locally advanced or metastatic solid tumors refractory to standard-of-care treatment. To advise on the clinical development strategy for IMGS-001 and other pipeline agents, the company is proud to announce the appointment of a six-member Scientific Advisory Board (SAB) who recently met to review our clinical data and provide input on the upcoming next phase of the IMGS-001 Phase 1a/ 1b study. "These distinguished members are true leaders in the field of immuno-oncology and come from some of the world's most prestigious cancer centers," said James Barlow , President and CEO of ImmunoGenesis. "I'm honored that the company can collaborate with this esteemed group of scientific and clinical experts whose insights will be instrumental in maximizing the potential of our lead agent to make a meaningful impact in treating some of the most challenging cancers." More details on the newly formed SAB are at the following link: About ImmunoGenesis ImmunoGenesis is a clinical-stage biotech company dedicated to transforming immuno-oncology by targeting key mechanisms of immune resistance. The company's lead product, IMGS-001, is a cytotoxic, dual-specific PD-L1/PD-L2 antibody currently in a Phase 1a/b clinical trial for the treatment of immune-excluded ("cold") tumors, which account for more than half of all cancers. In addition to its lead program, the company has a second clinical asset, IMGS-101 that has the potential to reverse tumor hypoxia, a major immunosuppressive element in solid tumors. The company has additional agents in the pipeline which represent novel approaches to overcome immune resistance in cold tumors. ImmunoGenesis designs therapies to address the pathology of these tumors, overcoming immune exclusion to elicit a robust immune response. For more information, visit About IMGS-001, a PD-L1/PD-L2 Dual-Specific Inhibitor IMGS-001 is a PD-L1/PD-L2 dual-specific inhibitor with engineered cytotoxic effector function. It is the first molecule to target PD-L2 in addition to PD-L1, potentially shutting down the entire PD-1 pathway and providing a superior blockade compared to other PD-1 or PD-L1 inhibitors. Its engineered effector function enables IMGS-001 to kill immunosuppressive PD-L1- and/or PD-L2-expressing cells present in the tumor microenvironment, providing the potential to overcome immune resistance in immune-excluded tumors. Preclinical data showed that IMGS-001 drove superior survival rates and tumor growth inhibition in head-to-head studies compared to currently available immunotherapies. With its cytotoxic killing function and superior blockade, IMGS-001 may provide a new foundation for combination immuno-oncology therapies. This Phase 1a/b study is being conducted with support from an investment from the Cancer Focus Fund, LP and the Cancer Prevention and Research Institute of Texas (CPRIT) DP200094. Disclosures MD Anderson's relationship with ImmunoGenesis, and all research conducted at MD Anderson related to ImmunoGenesis, has been identified as an institutional financial conflict of interest by MD Anderson's Institutional Conflict of Interest Committee and is managed under an Institutional Conflict of Interest Management and Monitoring Plan. Dr. Curran and Dr. Hong receive compensation as members of the Immunogenesis SAB, and these financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee in accordance with institutional policy. Contact ImmunoGenesis Investors: James Barlow President and CEO
